It starts with a regimen that some patients prefer
In SOLAR, every-2-month CABENUVA was preferred by 9 out of 10 survey respondents vs daily oral therapy with BIKTARVY1,2
At Month 12 analysis or study withdrawal (secondary endpoint), all CABENUVA-treated patients in SOLAR (mITT-E; n=447) were asked to respond to a question about which regimen they preferred. 22 patients did not respond. Of the 425 survey respondents2:

Identifying patients for
CABENUVA in your practice
HBV=hepatitis B virus; IM=intramuscular; INSTI=integrase strand transfer inhibitor; IQR=interquartile range; ITT-E=intent-to-treat exposed; M=month; mITT-E=modified intent-to-treat exposed; SWI=starting with injections.
References:
- Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):E566-E577. doi.org/10.1016/S2352-3018(23)00136-4
- Data on file. ViiV Healthcare group of companies. Durham, NC.
- ClinicalTrials.gov. SOLAR Study. Available at: https://clinicaltrials.gov/ct2/show/NCT04542070. Accessed February 16, 2023.
CBRWCNT230036